Extended Data Fig. 4: Phenotype of CD8 + TILs in mice with AT3 and B16 tumors.
(a) Representative spectrum plots of CD39+CD73+ CD8+ T cells in dLNs of Y- and A- C57BL/6J mice with B16 and AT3 tumors and (b) frequency of CD39+CD73+ CD8+ T cells in dLNs of BALB/cByJ mice with 4T1.2 and EMT6 tumors. (c–f) Comparative contour plots for co-expression of selected surface markers in DP8 and SP39 cells in dLNs (c and d) and TILs (e and f) of Y- (upper) and A- (lower panels) mice with AT3 (c, e) and B16 (d, f) tumors. Red and Blue arrows and numbers are for expression of indicated markers in CD39+CD73+ (DP8) and CD39+ CD73− (SP39) cells, respectively. (g and h) DP8 cells acquire exhausted phenotype in TME. Sorted LN and splenic DP8 cells from Y-WT mice were labeled with eFluor450 and i.v. injected into A-WT mice with 12-day old AT3 tumor (h-i, Schema of the experiment (Image was created using BioRender.com) and gating strategy for cells used, h-ii), Representative dot plots showing the expression of indicated markers in the host DP8 and SP39 cells in LNs of tumor-free (LN naïve) and tumor-bearing A-WT mice (ndLN, dLN) and the tumor tissue (TIL, g). (Shown is mean number or frequency ± SEM (b), where each symbol is for a single mouse, n = 5-12 (b) mice per group. Experiments were reproduced three times. ** P < 0.01; *** P < 0.001 in unpaired Mann-Whitney test and Kruskal-Wallis test.
